Condition

Esophageal Squamous Cell Carcinoma (ESCC)

ClinicalTrials.gov condition label

Clinical trials7
Recruiting3
Common interventions18
Lead sponsors shown6

Clinical trials

7 shown
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsNCT07189871 · 2026-02-23
RECRUITING
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid TumorsNCT07085091 · 2025-08-18
RECRUITING
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected MalignanciesNCT05473156 · 2023-07-24
RECRUITING
Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell CarcinomaNCT07147361 · 2025-09-12
ACTIVE_NOT_RECRUITING
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)NCT05342636 · 2022-07-27
COMPLETED
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)NCT04210115 · 2020-02-28
COMPLETED
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid TumorsNCT03708328 · 2018-10-15
COMPLETED

Trial status mix

COMPLETED3
RECRUITING3
ACTIVE_NOT_RECRUITING1

Phase mix

PHASE15
PHASE23
PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.